Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

U. Demirci



Author of

  • +

    P1.10 - Poster Session 1 - Chemotherapy (ID 204)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.10-007 - Biweekly Cisplatin And Gemcitabine As First-Line Treatment in Advanced Non-Small Cell Lung Cancer (ID 671)

      09:30 - 09:30  |  Author(s): U. Demirci

      • Abstract

      Background
      Non-small cell lung cancer (NSCLC) is the most common cancer worldwide. Majority of the patients present with advanced disease. For patients with good performance status, palliative chemotherapy consisting of a platinum-containing doublet has become Standard of care. Cisplatin plus gemcitabine is a viable option in the treatment of metastatic NSCLC. Biweekly use of this regimen has been found to be effective and tolerable in various cancers. Moreover, this schedule offers a more convenient way of administration. We retrospectively evaluated the efficacy and tolerability of this regimen in advanced NSCLC patients.

      Methods
      Medical records of advanced NSCLC patients who were treated with first-line biweekly cisplatin + gemcitabine chemotherapy were analyzed retrospectively. Cisplatin 50 mg/m2 and gemcitabine 1000 mg/m2 were given on day 1 of every 14 days of the cycle. Response rates, survival outcomes and toxicities were recorded.

      Results
      A total of 109 patients were evaluated in six centers of Anatolian Society of Medical Oncology. Of those, 94 patients were men (86%) and 15 were women (14%). The median age was 58 years (range, 25-82). Most of the patients had adenocarcinoma (n=62, 57%). All of them had ≤2 ECOG PS. Median 7 cycles therapy were given (range, 2-12). Patients were evaluated for response usually after every 4 cycles. There was no complete response. Forty-five patients (41%) achieved partial response (PR). Stable disease was observed in 27% of the patients leading to an overall clinical benefit rate of 68%. Median progression-free survival (PFS) was 5.9 months. Median overall survival (OS) was 12.6 months. Eight patients died due to progression during therapy. The most common non-hematologic toxicities were nausea and vomiting. Grade 3/4 toxicity was detected in eight (7%) patients. They were four anemias, two neutropenias, one vomiting and one nephropathy. In all grades, the most common hematologic toxicity was anemia (48%). Neutropenia was seen in 21% of the cases, but only one patient had febrile neutropenia. One patient had to discontinue therapy due to grade 2 nephropathy.

      Conclusion
      Biweekly cisplatin and gemcitabine is an effective and tolerable regimen in the first-line treatment of NSCLC.

  • +

    P2.06 - Poster Session 2 - Prognostic and Predictive Biomarkers (ID 165)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Biology
    • Presentations: 1
    • +

      P2.06-006 - Clinical and Prognostic Importance of XIAP and USP8 in Advanced Stages of Non-Small Cell Lung Cancer (ID 669)

      09:30 - 09:30  |  Author(s): U. Demirci

      • Abstract

      Background
      Apoptotic pathways are controlled by activation or inhibition of the intracellular caspases. Inhibitor of apoptosis proteins (IAPs) are endogenous inhibitors of caspase activity. We aimed to investigate the relationship of the apoptosis regulators X-linked inhibitor of apoptosis (XIAP) and ubiquitin specific protease 8 (USP8) with clinical parameters, survival and response to chemotherapy in advanced stages of non-small cell lung cancer (NSCLC).

      Methods
      A total of 34 NSCLC patients (28 males, 6 females) and 44 healthy volunteers were included in the study. Most of the patients had squamous cell histology (62%), while others had adenocarcinoma (29%) and unclassified (8%) types. All patients had locally advanced stage IIIA-IIIB (50%) or metastatic (50%) disease. XIAP and USP8 levels were measured by ELISA method.

      Results
      The median serum XIAP levels were similar in patients and the controls (p=NS). USP8 level was higher in patients compared to the control group (p<0.0001). In univariate analysis, there was no significant relationship between XIAP and USP8 serum levels and age, sex, performance status, weight loss, stage of disease, histopatological type and response to chemotherapy. In the low and high XIAP and USP8 groups, there was no significant difference in progression-free survival (PFS) (p=0.432 and p=0.50, respectively) and overall survival (OS) (p=0.989 and p=0.90, respectively).

      Conclusion
      No relationship was found with serum XIAP and USP8 levels and clinical parameters, response to chemotherapy, PFS and OS in patients with advanced stages of NSCLC.